Category Archives: Pharmacogenomics

Please enable Javascript to watch this video

PALO ALTO, California One medical center has developed an innovative program that uses new technology, genetics, and other tools to personalize care.

For Debbie Spaizman, it means actually getting the help she needs.

She needed surgery, but she hesitated due to how she reacted to pain medication.

"My head would spin. I really was foggy, and I had itching all over my body," she explained.

"I had no pain relief at all. I thought twice about having the surgery."

To get answers, Debbie enrolled in the HumanWide Project at Stanford Medical School.

The study flips the model on healthcare by personalizing treatment.

That includes a deep dive into pharmacogenics.

"Pharmacogenomics specifically tests for genes that look at the rate in which we metabolize drugs," said Dr. Megan Mahoney, Clinical Professor of Medicine at Stanford University.

"It can determine the dosing of medications and also predict any side effects."

That means our genes can play a big role in how we respond to medicine.

And so, with a quick swab of the cheek, Debbie finally got answers.

"The result of the test showed that I'm a slow metabolizer. Drugs will stay in my system longer than they will for someone else."

With that, a plan started to come together for Debbie.

"We were able to identify the class of opioids that would work for her based on her pharmacogenomic make-up and then she was able to go through with the surgery," said Dr. Mahoney.

Debbie is grateful.

"It was life changing for me."

And she's not the only one.

"25% of patients had a change in their dose of medication based on the pharmacogenomics test," said Dr. Mahoney.

It's an approach that Debbie calls an "absolutely game changer."

Stanford is not the only one paying attention to pharmacogenics.

The US Department of Veteran Affairs is making a big push to personalize medicine for its vets.

The program will enroll those with a history of cancer, but will also inform doctors how patients will metabolize other medicines they need.

If this story has impacted your life or prompted you or someone you know to seek or change treatments, please let us know by contacting Jim Mertens at jim.mertens@wqad.com or Marjorie Bekaert Thomas at mthomas@ivanhoe.com.

More:
YOUR HEALTH: What can be done when the medicines you need make you even sicker? - WQAD Moline

Global Vascular Patches Market Report Market Size, Share, Price, Trends and Forecast is a professional and in-depth study on the current state of the global Vascular Patches industry.

The report also covers segment data, including: type segment, industry segment, channel segment etc. cover different segment market size, both volume and value. The compilation also covers information about clients from different industries, which is very important for the manufacturers.

There are 4 key segments covered in this Vascular Patches market report: competitor segment, product type segment, end use/application segment, and geography segment.

Request Sample Report @ https://www.marketresearchreports.biz/sample/sample/6900?source=atm

Quantifiable data:-

Geographically, this report studies the top producers and consumers, focuses on product capacity, production, value, consumption, market share and growth opportunity in these key regions, covering North America, Europe, China, Japan, Southeast Asia, India Companies

The information for each competitor includes:

* Company Profile

* Main Business Information

* SWOT Analysis

* Sales, Revenue, Price, and Gross Margin

* Market Share

Send Enquiry On This Report @ https://www.marketresearchreports.biz/sample/enquiry/264?source=atm

key players operating in the market during the forecast period, primarily due to the rise in patient pool for the condition. Biologic vascular patches offer several benefits over synthetic vascular patches, in terms of reduced rates of infection, biocompatibility, and ease of use. Based on end-user, the global vascular patches market can be segregated into specialty clinics, hospitals, ambulatory surgical centers, and others

Based on geography, the global vascular patches market can be segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. Furthermore, the North America vascular patches market can be split into U.S., and Canada. The vascular patches market in Europe can be further bifurcated into U.K., Germany, France, Italy, Spain, and Rest of Europe. The Asia Pacific vascular patches market is further sub-segmented into Japan, India, China, Australia & New Zealand, and Rest of Asia Pacific. The vascular patches market in Latin America can be further split into Mexico, Brazil, and Rest of Latin America. The Middle East & Africa Vascular Patches market can be sub-segmented into Saudi Arabia, Israel, South Africa, and Rest of Middle East & Africa. North America dominated the global vascular patches due to factors such as Increase in incidence of target diseases, rise in per capita health care expenditure, shift in focus of governments toward providing better health care facilities, advanced technological innovations, and rise in medical tourism. The market in Asia Pacific is anticipated to expand at a rapid pace during the forecast period owing to factors such as increasing awareness regarding advanced vascular products and the presence of a large patient population.

Major players operating in the global vascular patches market include Labcor Laboratrios Ltda, LeMaitre Vascular, Inc., Terumo Corporation, Becton, Dickinson and Company, B. Braun Melsungen AG, MAQUET Holding B.V. & Co. KG, W. L. Gore & Associates, Inc., Admedus, CryoLife, Inc., Baxter, and Edwards Lifesciences Corporation.

MRR.BIZ has been compiled in-depth market research data in the report after exhaustive primary and secondary research. Our team of able, experienced in-house analysts has collated the information through personal interviews and study of industry databases, journals, and reputable paid sources.

The report provides the following information:

The main aim of the report is to:

MRR.BIZ is a leading provider of strategic market research. Our vast repository consists research reports, data books, company profiles, and regional market data sheets. We regularly update the data and analysis of a wide-ranging products and services around the world. As readers, you will have access to the latest information on almost 300 industries and their sub-segments. Both large Fortune 500 companies and SMEs have found those useful. This is because we customize our offerings keeping in mind the specific requirements of our clients.

Important key questions answered in Vascular Patches market report:

What will the market growth rate, overview, and analysis by type of global Vascular Patches in 2029?

What are the key factors affecting market dynamics? What are the drivers, challenges, and business risks in Vascular Patches market?

What is dynamics, this overview includes analysis of scope and price analysis of top manufacturers profiles?

What are the opportunities, risks, and the driving forces behind of Vascular Patches market? What are the major upstream raw materials sourcing and downstream buyers?

What is the business overview by type, applications, gross margin, and market shares?

What are the opportunities and threats faced by manufacturers in the global Vascular Patches market?

Check Discount On This Report @ https://www.marketresearchreports.biz/sample/checkdiscount/6900?source=atm

We are a vibrant market research company which is focused on catering to more and more people day by day. Our research company is one of a few reliable market research report companies in todays date.

Visit link:
Global Pharmacogenomics (PGx) Market Research Report 2020 Overall Analysis and Forecast up to 2025 - Fusion Science Academy

Bloomberg--Whats the medical breakthrough that could save the most lives in the U.S. over the next ten years? In the 2020s, medical research will likely inch forward when it comes to major killers like heart disease and cancer. But the biggest potential to save lives could lie in learning to prevent suicide.

The rates of reported suicides have been creeping up over the last two decades. Even more disturbingly, CDC reports that the suicide death rate for teens increased 56 percent between 2007 and 2017. Rising suicide rates might be a result of many things rising levels of despair, the opioid epidemic, greater access to guns, even the proliferation of Internet groups that offer people advice on how to kill themselves. It could also be that more people are reporting suicides instead of concealing such deaths as accidents.

Its a surprisingly common form of deathmore prevalent than homicide or automobile accidents. Unlike cancer and heart disease, which are leading causes of death among the old, suicide robs people of decades of life. According to CDC statistics, it is the second most prevalent cause of death, after accidents, for people between 10 and 34 and fourth for people between 34 and 54.

Because it hasnt been all that thoroughly studied as a medical problem, theres room to cut down on that death toll even without any remarkable technological breakthrough. A streamlined three-digit suicide hotline number, approved last month by FCC, could become one of the great public health measures of the century. Further out on the frontier, researchers are having some success using artificial intelligence to identify suicidal peoplethose whose lives might be saved by talk therapy or drugs.

John Pestian, director of the computational medicine center at Cincinnati Childrens Hospital, explains that there are different kinds of suicides. Some are driven primarily by chronic mental illness, while others are more impulsive. Those with chronic mental illness may make repeated attempts. People have a powerful instinct to live, he says, and for their psychological pain to override this, it must be incredibly intense. Hes hoping to help such people through pharmacogenomicsfinding drugs that will ease their chronic emotional pain.

The more impulsive cases are simpler to preventthink of the teenager whose boyfriend or girlfriend just left, or a Wall Street trader who lost all his money, he says. If someone is going through an acute crisis and wants to jump out a window, the right words spoken at the right time might be the only treatment needed to save a life.

Renowned suicide researcher Edwin Schneidman writes in The Suicidal Mind that therapists can help people in this state by getting them to consider alternatives besides killing themselveshelping them see that that they have choices. He describes how he helped a suicidal college student who felt hopeless after she found out she was pregnant. He got her to consider which of her options was least terrible, and she recovered.

In the memorable 2003 New Yorker story Jumpers, Tad Friend describes conversations with several people who survived after jumping off the Golden Gate Bridge. They told him that they recognized their mistake before they hit the water: I instantly realized that everything in my life that Id thought was unfixable was totally fixableexcept for having just jumped, one said. Another left a note saying Im going to walk to the bridge. If one person smiles at me on the way, I will not jump.

To learn more about the reasons people decide to take their own lives, Pestian and other researchers are amassing troves of data. Right now, he says, he has the biggest collection of suicide notes in the country, as well as samples of speech and body language from suicidal patients. There are clues in these that therapists can look forand patterns that algorithms can use to identify those most at risk.

He says suicide hotlines are crucial, and he approves of the idea of amending the current one, created in 2005, from the usual ten digits to just three: 988. Even so, its not quite as simple as it sounds, he says: there will also have to be the right kinds of resources at the other end of the line.

According to one news story, an FCC committee estimated that those resources would cost $570 million in the first year and $175 million the next. This is pocket change compared with, say, routine mammography, which costs Americans billions and the value of which has been called into question.

As for AI, using algorithms to predict anyones behavior can sound scary, especially the use of systems that attempt to label Facebook users as suicidal from their posts or others that gather data from users smartphones. But Pestian believes that theres potential for AI to do much good in the area of suicide, as long as its only used to support human decision-making, and humans dont delegate the decision making to machines.

He has developed algorithms that work with what he calls sentiment dataacoustic, visual or language patterns that differ between the suicidal and non-suicidal. In a paper published in 2016 in the journal Suicide and Life-Threatening Behavior, he applied an algorithm to interviews with a sample of 379 people, some known to be suicidal, some diagnosed with mental illness but not suicidal, and a healthy control group. The algorithm used speech, facial expressions and body language to identify the suicidal group with 85 percent accuracy.

Thats not perfect, but its better than doctors can do. Pestian has recently gotten a contract with Oak Ridge National Laboratory to apply AI to the rampant problem of suicide among veterans. According to a report from the U.S. Department of Veterans Affairs, more than 6,000 veterans die by suicide every yeara rate 50 percent higher than that in the general adult population.

We may not know the reason for the rising suicide rate, but we do know it is killing too many people, and that those deaths ought to be preventable. While science has a pretty detailed understanding of cancer and heart problems, suicide was studied by relatively few researchers until recently.

Read the original post:
Suicide research could be the mortality breakthrough of the 2020s - Health Data Management

In the future, nutritionists and dietitians will have a new tool for studying the relationship between a persons nutrition and health theyll be adding DNA into the mix.

Manchester University is moving ahead with plans to offer a master of science degree in nutrition and nutrigenomics (MSNGx).

It builds on Manchesters masters degree in pharmacogenomics, which is the study of DNA and medication. Manchester is the first university in the nation to offer that degree.

To our knowledge, the MSNGx program would be the first of its kind in the country, said Teresa Beam, Pharmaceutical Sciences Department chair and professor of pharmaceutical sciences and pharmacogenomics at Manchesters Fort Wayne campus.

Manchester University will train the nutritionist of the future, she said. The program will be divided into two phases: three years of undergraduate study at the North Manchester campus and two years of professional study at the Fort Wayne campus.

Jeff Beer will be responsible for the first three years the undergraduate phase. Beam will lead the graduate-level phase in Fort Wayne.

In lay terms, the program will teach nutritionists how to use an individuals DNA to make better nutrition choices. Beam said eventually, with additional research the body of evidence will grow and nutritionists and dietitians will be better able to match diets to genes, the gut microbiome and metabolism.

The ultimate goal of this new field, Beam said, is to use nutrigenomics to improve health and make healthier communities. Complex diseases such as cancer, diabetes and heart disease could some day be better managed when an NGx-trained nutritionist is part of patients health care teams.

The importance of diet in preventing and treating complex diseases is well-known, she said. Food as medicine is emerging as a necessary component of managing complex diseases.

In Spring 2020 the university plans to hire an MSNGx program director. By the end of 2020 the MSNGx application should be submitted to the accrediting council. The accreditation site visit will be in spring of 2022 and the first students will be admitted in fall 2022.

Nutrigenomics also has the potential to improve athletic performance. Genetics can influence the bodys ability to recover from injury, generate inflammation or cause oxidative stress, Beam said. Genetics can also affect performance. All are factors that can be considered when constructing athletic training regimens, designing physical therapy treatments or optimizing game strategies.

Read more from the original source:
Manchester to add master's degree in nutrition with DNA twist - FW Business

Los Angeles, United State,January 2020 :

The report attempts to offer high-quality and accurate analysis of the global Pharmacogenomics (PGx) market, keeping in view market forecasts, competitive intelligence, and technological risks and advancements, and other important subjects. Its carefully crafted market intelligence allows market participants to understand the most significant developments in the global Pharmacogenomics (PGx) market that are impacting their business. Readers can become aware of crucial opportunities available in the global Pharmacogenomics (PGx) market as well as key factors driving and arresting market growth. The research study also provides deep geographical analysis of the global Pharmacogenomics (PGx) market and sheds light on important applications and products that market players can focus on for achieving strong growth.

Major players profiled in the report

We follow industry-best practices and primary and secondary research methodologies to prepare our market research publications. Our analysts take references from company websites, government documents, press releases, and financial reports and conduct face-to-face or telephonic interviews with industry experts for collecting information and data. There is one complete section of the report dedicated for authors list, data sources, methodology/research approach, and publishers disclaimer. Then there is another section that includes research findings and conclusion.

Get PDF template of Pharmacogenomics (PGx) market report@ https://www.qyresearch.com/sample-form/form/994732/global-Pharmacogenomics-PGx-market

This report focuses on the global top players, coveredAbbott LaboratoriesAffymetrix, Inc.Assurex Health, IncAstrazenecaGeneDXIllumina, Inc.Laboratory Corporation of America HoldingsMyriad Genetics, Inc.Pathway GenomicsPfizer, IncQiagen, Inc.RochegTeva Pharmaceutical Industries Ltd.Thermo Fisher ScientificTransgenomic, Inc.

Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaRest of Asia PacificCentral & South AmericaMiddle East & Africa

Market segment by Type, the product can be split intoPolymerase Chain Reaction (PCR)MicroarraySequencingOther

Market segment by Application, the market can be split intoCardiovascular Diseases (CVD)Central Nervous System (CNS)Cancer/OncologyInfectious DiseasesOther

Market Forecasting

Besides short-term and long-term estimations related to the global Pharmacogenomics (PGx) market, we provide you with demand, consumption, growth, and various other forecasts. We take your specific requirements into consideration and provide you the most applicable forecasts for the market. You can simplify your critical decision-making process using our forecasts on the global market. Our unbiased insights into critical aspects of the market will assist you to strengthen your market position and ensure lasting success in the long run. They will also help you to address the challenges you face in the market when reaching your milestones.

Customized Research

Our analysts are not only experts in preparing accurate and detailed market research reports but also customizing them according to your business needs. We can customize this entire report on the global Pharmacogenomics (PGx) market and also specific sections such as financial analysis, competitive intelligence, insights and innovation, target market analysis, strategy and planning, and market analysis. Our report customization can cover merger and acquisition screening, IPO prospectus, economic impact analysis, industry benchmarking, competitive landscape, due diligence, and company analysis.

Apart from the sections mentioned above, our report on the global Pharmacogenomics (PGx) market can be customized keeping in view other aspects such as research and development landscape, patent analysis, product competition, mega trend analysis, marketing mix modeling, go-to-market strategy, technology, B2B survey, and strategic frameworks. Furthermore, you can ask for customization of market scenario analysis, strategic recommendations, market potential analysis, identification of opportunities, market forecasting, market entry, market sizing, market attractiveness, and market segmentation.

Table of Contents

Study Coverage: This is the first section of the report that includes highlights of market segmentation, years covered, study objectives, major manufactures of the global Pharmacogenomics (PGx) market, and product scope.

Executive Summary: Here, the report sheds light on production, revenue, consumption, and capacity of the market. It also brings to light macroscopic indicators, drivers, restraints, and trends of the market.

Manufacturer Profiles: This section gives broad analysis of key players of the global Pharmacogenomics (PGx) market on the basis of different factors such as recent developments, market share, and gross margin. It also provides SWOT analysis.

Production by Region: All of the regions analyzed in the report are studied here based on key factors such as production, revenue, market share, and import and export.

Consumption by Region: Each regional market studied here is analyzed on the basis of consumption and consumption share of the global market.

Market Size by Product: It includes price, revenue, and market breakdown analysis by type of product.

Market Size by Application: It includes consumption, breakdown data, and consumption share analysis by application.

The report answers several questions about the Pharmacogenomics (PGx) market includes:

What will be the market size of Pharmacogenomics (PGx) market in 2025?What will be the Pharmacogenomics (PGx) growth rate in 2025?Which key factors drive the market?Who are the key market players for Pharmacogenomics (PGx)?Which strategies are used by top players in the market?What are the key market trends in Pharmacogenomics (PGx)?Which trends and challenges will influence the growth of market?Which barriers do the Pharmacogenomics (PGx) markets face?What are the market opportunities for vendors and what are the threats faced by them?What are the most important outcomes of the five forces analysis of the Pharmacogenomics (PGx) market?

Get Customized Report in your Inbox within 24 hours@ https://www.qyresearch.com/customize-request/form/994732/global-Pharmacogenomics-PGx-market

Contact US:QY Research, INC.17890 Castleton, Suite 218,Los Angeles, CA 91748USA: +1 626 295 2442China: +86 1082 945 717Japan: +81 9048 009 273India: +91 9766 478 224Emails enquiry@qyresearch.com

Read more:
Global Pharmacogenomics (PGx) by leading manufacturers with its application and types 2020 2025| Abbott Laboratories, Affymetrix, Inc. - News Log...

We don't always get what we want. But that shouldn't stop us from wishing, right?

So we reached out to executives around healthcare to get their wish lists for the industry as we enter the next decade.

From taking on regulatory requirements to better harnessing telehealth, here's what they had to say.

Top health industry issues of 2020: Will digital start to show an ROI?

Each year, PwC's Health Research Institute (HRI) names the top issues for the health industry in the coming year. What made the list for 2020? Join HRI for a discussion of the most important trends for providers, insurers, pharma/life sciences and employers.

"With the continued focus on bringing down the cost of healthcare, payers and employers will increasingly join providers in urging people to access the right level of care in lower-acuity settings rather than going to the ED. This will continue the acceleration of consumer-direct access to care options such as in-home, digital and local retail locations."

We need to move away from politics as usual. It is my hope that we can come together to drive solutions that make our healthcare system more efficient and prioritize the patients needs above all. Lets remove regulatory requirements to empower providers to focus on the delivery of care instead of needless administration. As the worlds largest economy, we simply have to prioritize the health of all of our people."

Lloyd Dean, co-CEO of CommonSpirit Health

"Top of mind is increased focus on using telehealth to meet the needs of the most vulnerable: the oldest and youngest on the spectrum as well as the sickest and poorest.

Weve gotten good at targeting telehealth to younger, tech-savvier, affluent patients in their 20s, 30s and 40s. But we need to pay closer attention to where telehealth is needed most and can have a profound impact. Telehealth holds strong potential to help patients with serious and chronic conditions, such as cancer, diabetes and COPD, who typically require more frequent engagement to stay out of the hospital.

Roy Schoenberg, M.D., president and CEO, American Well

"Id like to see the industry adopt more care management policies that encourage patients to manage their safety, healthcare and data via tested digital applications. In 2020 there should be greater adoption and more rapid application of pharmacogenomics into workflow process for patients and prescribers. The fact that the FDA is holding back pharmacogenomics is short-sighted. Pharmacogenomics ought to be fully embraced along with pharmacists who use technology-enabled tools to clinically apply data real-time and store data for future use as well.

Care practices should also be expanded so that pharmacists can be first-line primary care providers through physician collaboration or on their own. As healthcare organizations and payers transform how healthcare is defined and paid for, it will essential for pharmacists to step out from behind the counter to play a larger role in advising care, managing treatment and other clinical care services such as approving refills based on certain parameters."

Orsula V. Knowlton, president, chief marketing/new business development officer,Tabula Rasa HealthCare

"With impeachment looming and the 2020 presidential election set to take center stage, it will be hard for antimicrobial resistance to break through the noise in the media. I hope to read that Washington lawmakers put partisan politics aside and prioritize policies that will save millions of lives. When it comes to legislation to fight superbugs, we need a package of incentivesincluding Medicare reimbursement reforms, pull incentives to reward FDA approval of novel antimicrobials and push incentives to support research and development programs.

The Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act is a good first step. The DISARM Act would increase Medicare funding to hospitals that appropriately use innovative antibiotics. The Centers for Medicare & Medicaid Services recently finalized a rule that would allow hospitals to receive additional Medicare reimbursement for prescribing newer antibiotics to treat drug-resistant infections. I hope to see more policy solutions that build on the DISARM Act to incentivize drug companies to fund antibiotic research."

GregFrank, director of Working to Fight AMR

See the article here:
We asked health execs for their 2020 wish lists. Here's what they said - FierceHealthcare